|
There are numerous benefits for Canadian patients that accrue from the MCRN program. These are some of the major advantages highlighted:
- Increasing access to more trials, in more centres across Canada.
- Allowing patients access to new molecules or treatment combinations not yet approved by Health Canada.
- Allowing patients access to new molecules or treatment combinations that are not yet reimbursed by the government or insurance policies.
- Ensuring the patient voice is heard through patient representation on the Clinical Trial Steering Committee and the Protocol Review Committee.
- Providing real word evidence through the MCRN National Myeloma database to help guide clinical decision-making, ultimately improving patient outcomes.
- Promoting coast-to-coast collaboration, allowing researchers quick access to shared findings and data allowing for improved diagnosis and optimal treatment management.
- Hosting clinical research in Canada may accelerate new treatment approvals by government bodies, by providing real-world Canadian evidence and data.
|
